Patents by Inventor Tatsuhiko Fujimoto

Tatsuhiko Fujimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compound and application thereof
    Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Substituted piperidine compound and use thereof
    Patent number: 11292766
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: April 5, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20220081399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: January 21, 2021
    Publication date: March 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20210269420
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
  • Substituted piperidine compound and use thereof
    Patent number: 10898737
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Hiromichi Sugimoto, Takahiro Matsumoto
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • 1,2-substituted cyclopentanes as orexin receptor antagonists
    Patent number: 10689373
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: June 23, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20200115399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Substituted piperidine compound and use thereof
    Patent number: 10508083
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 17, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20190263843
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Substituted piperidine compound and use thereof
    Patent number: 10287305
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: May 14, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Hiromichi Sugimoto, Takahiro Matsumoto
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20190031611
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: February 1, 2017
    Publication date: January 31, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20180282309
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 1, 2018
    Publication date: October 4, 2018
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • 1,2-substituted cyclopentanes as orexin receptor antagonists
    Patent number: 10011588
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
    Patent number: 9790220
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, Tatsuhiko Fujimoto, John Stephen Robinson
  • SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF
    Publication number: 20170226137
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 10, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170073340
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, Formula (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 19, 2015
    Publication date: March 16, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, Tatsuhiko Fujimoto, John Stephen Robinson
  • 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20170066744
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L, X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 19, 2015
    Publication date: March 9, 2017
    Inventors: Charlotte Fieldhouse, Angela Glen, Stephanie Maine, Tatsuhiko Fujimoto, John Stephen Robinson
  • Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders
    Patent number: 9493432
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: November 15, 2016
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventors: Charlotte Fieldhouse, Angela Glen, John Stephen Robinson, Tatsuhiko Fujimoto
  • Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders
    Publication number: 20160222030
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 4, 2016
    Inventors: Charlotte Fieldhouse, Angela Glen, John Stephen Robinson, Tatsuhiko Fujimoto